Tezacaftor
In clinical developmentAlso known as Alyftrek.
Recent clinical, regulatory, research and industry developments relating to this drug.
A Phase 1, Study of VX-828 in Healthy Subjects and in Subjects With Cystic Fibrosis
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes1
Journals, researchers & institutions
- Respiratory research1
- Conrad D1
- Gil M1
- Gonzalez CT1
- Guzior DV1
- Martin C1
- McClelland M1
- Mielke J1
- Okros M1
- Medical University of Vienna1
- Michigan State University1
- University of California San Diego1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Acts on the same molecular target as Tezacaftor, with an overlapping disease area.
Acts on the same molecular target as Tezacaftor, with an overlapping disease area.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials